WO2008138578A3 - Methods, kits, and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy - Google Patents
Methods, kits, and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy Download PDFInfo
- Publication number
- WO2008138578A3 WO2008138578A3 PCT/EP2008/003789 EP2008003789W WO2008138578A3 WO 2008138578 A3 WO2008138578 A3 WO 2008138578A3 EP 2008003789 W EP2008003789 W EP 2008003789W WO 2008138578 A3 WO2008138578 A3 WO 2008138578A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- kits
- devices
- treatment
- methods
- identifying biomarkers
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA
Abstract
The present invention features methods, kits, and devices for predicting the sensitivity of a patient to a compound or medical treatment. The invention also features methods for identifying gene biomarkers whose expression correlates to treatment sensitivity or resistance within a patient population or subpopulation.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DKPA200700714 | 2007-05-11 | ||
DKPA2007/00714 | 2007-05-11 | ||
DKPA2007/01023 | 2007-07-11 | ||
DKPA200701023 | 2007-07-11 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2008138578A2 WO2008138578A2 (en) | 2008-11-20 |
WO2008138578A3 true WO2008138578A3 (en) | 2009-03-05 |
Family
ID=39711924
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2008/003789 WO2008138578A2 (en) | 2007-05-11 | 2008-05-09 | Methods, kits, and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2008138578A2 (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7897356B2 (en) | 2008-11-12 | 2011-03-01 | Caris Life Sciences | Methods and systems of using exosomes for determining phenotypes |
US8700335B2 (en) | 2006-05-18 | 2014-04-15 | Caris Mpi, Inc. | System and method for determining individualized medical intervention for a disease state |
US8768629B2 (en) | 2009-02-11 | 2014-07-01 | Caris Mpi, Inc. | Molecular profiling of tumors |
US8927700B2 (en) | 2009-08-21 | 2015-01-06 | Gilead Biologics, Inc. | Catalytic domains from lysyl oxidase and LOXL2 |
US9107935B2 (en) | 2009-01-06 | 2015-08-18 | Gilead Biologics, Inc. | Chemotherapeutic methods and compositions |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030114410A1 (en) | 2000-08-08 | 2003-06-19 | Technion Research And Development Foundation Ltd. | Pharmaceutical compositions and methods useful for modulating angiogenesis and inhibiting metastasis and tumor fibrosis |
US8461303B2 (en) | 2007-08-02 | 2013-06-11 | Gilead Biologics, Inc. | LOX and LOXL2 inhibitors and uses thereof |
WO2009080437A1 (en) * | 2007-12-21 | 2009-07-02 | Exiqon A/S | Micro-rna based drug resistance analysis method |
TW200951219A (en) | 2008-05-06 | 2009-12-16 | Academia Sinica | An improved SUMO fusion protein system for effective production of native proteins |
CA2742324A1 (en) | 2008-10-30 | 2010-06-03 | Caris Life Sciences Luxembourg Holdings, S.A.R.L. | Methods for assessing rna patterns |
JP2012039876A (en) * | 2008-12-26 | 2012-03-01 | Univ Of Tokushima | Prediction of effectiveness of preoperative chemoradiotherapy on rectal cancer using micro-rna |
EP2432896A1 (en) * | 2009-05-18 | 2012-03-28 | INSERM - Institut National de la Santé et de la Recherche Médicale | A method for predicting the responsiveness of a patient to a treatment with an anti-cd20 antibody and a method for diagnosing rheumatoid arthritis |
DK177532B1 (en) | 2009-09-17 | 2013-09-08 | Bio Bedst Aps | Medical use of sPLA2 hydrolysable liposomes |
EP2333103A1 (en) * | 2009-12-11 | 2011-06-15 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Differential diagnosis and therapy for kinase inhibitors |
CA2791905A1 (en) | 2010-03-01 | 2011-09-09 | Caris Life Sciences Luxembourg Holdings, S.A.R.L. | Biomarkers for theranostics |
EP2556172A4 (en) | 2010-04-06 | 2013-10-30 | Caris Life Sciences Luxembourg Holdings | Circulating biomarkers for disease |
WO2011135459A2 (en) | 2010-04-29 | 2011-11-03 | Medical Prognosis Institute A/S | Methods and devices for predicting treatment efficacy |
NZ702485A (en) | 2010-06-03 | 2016-04-29 | Pharmacyclics Llc | The use of inhibitors of bruton’s tyrosine kinase (btk) |
JP5755849B2 (en) * | 2010-07-06 | 2015-07-29 | 東レ株式会社 | Composition or kit for determining sensitivity to adjuvant chemotherapy for gastric cancer |
US8895509B2 (en) | 2010-11-23 | 2014-11-25 | Georgia Tech Research Corporation | MIR-200 family induces mesenchymal-to-epithelial transition (MET) in ovarian cancer cells |
DK2532747T3 (en) * | 2011-06-09 | 2016-01-25 | Deutsches Krebsforsch | Modulators of glycerol-3-phosphate dehydrogenase (GPD2) in therapy |
EP3156505B1 (en) * | 2011-08-19 | 2019-07-17 | Hummingbird Diagnostics GmbH | Complex sets of mirnas as non-invasive biomarkers for colon cancer |
US20150148244A1 (en) * | 2011-09-08 | 2015-05-28 | Targeted Molecular Diagnostics, Llc | Methods for determining responsiveness to a dihydrofolate reductase inhibitor |
CA2879570A1 (en) | 2012-07-24 | 2014-01-30 | Pharmacyclics, Inc. | Mutations associated with resistance to inhibitors of bruton's tyrosine kinase (btk) |
EP2898099A4 (en) * | 2012-09-21 | 2016-05-25 | Singapore Health Serv Pte Ltd | Methods of diagnosing liver cancer in a subject and a kit for diagnosing liver cancer |
CN103784465B (en) * | 2012-11-02 | 2015-11-11 | 上海交通大学医学院附属瑞金医院 | Aldehyde dehydrogenase 2 is as the application of drug targets during anthracyclines process tumor cell |
US10261086B2 (en) | 2013-01-10 | 2019-04-16 | Amrita Vishwa Vidyapeetham | Differential cerebrospinal fluid reactivity to PFDN5-alpha for detection of B-cell acute lymphoblastic leukemia |
US20150361504A1 (en) * | 2014-06-13 | 2015-12-17 | Pharmacyclics Llc | Biomarker for predicting response of cll to treatment with a btk inhibitor |
FI3198035T3 (en) | 2014-09-26 | 2023-01-31 | Methods for predicting drug responsiveness | |
KR101674874B1 (en) * | 2014-10-21 | 2016-11-22 | 한국원자력의학원 | Icam-3 as biomarker for the prediction of resistance against anticancer agents and use thereof |
US9725769B1 (en) | 2016-10-07 | 2017-08-08 | Oncology Venture ApS | Methods for predicting drug responsiveness in cancer patients |
AU2017258901A1 (en) | 2016-12-30 | 2018-07-19 | Allarity Therapeutics Europe ApS | Methods for predicting drug responsiveness in cancer patients |
-
2008
- 2008-05-09 WO PCT/EP2008/003789 patent/WO2008138578A2/en active Application Filing
Non-Patent Citations (4)
Title |
---|
DAHLEN ANNA ET AL: "Activation of the GLl oncogene through fusion with the beta-actin gene (ACTB) in a group of distinctive pericytic neoplasms - Pericytoma with t(7;12)", AMERICAN JOURNAL OF PATHOLOGY, vol. 164, no. 5, May 2004 (2004-05-01), pages 1645 - 1653, XP002494073, ISSN: 0002-9440 * |
FOURNIER MARCIA V ET AL: "Gene expression signature in organized and growth-arrested mammary acini predicts good outcome in breast cancer", CANCER RESEARCH, vol. 66, no. 14, July 2006 (2006-07-01), pages 7095 - 7102, XP002494058, ISSN: 0008-5472 * |
KORNMANN MARKO ET AL: "Thymidylate synthase and dihydropyrimidine dehydrogenase mRNA expression levels: predictors for survival in colorectal cancer patients receiving adjuvant 5-fluorouracil", CLINICAL CANCER RESEARCH, THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 9, no. 11, 15 September 2003 (2003-09-15), pages 4116 - 4124, XP002391741, ISSN: 1078-0432 * |
VEER VAN 'T L J ET AL: "Gene expression profiling predicts clinical outcome of breast cancer", NATURE, NATURE PUBLISHING GROUP, LONDON, UK, vol. 415, no. 6871, 31 January 2002 (2002-01-31), pages 530 - 536, XP002259781, ISSN: 0028-0836 * |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8700335B2 (en) | 2006-05-18 | 2014-04-15 | Caris Mpi, Inc. | System and method for determining individualized medical intervention for a disease state |
US7897356B2 (en) | 2008-11-12 | 2011-03-01 | Caris Life Sciences | Methods and systems of using exosomes for determining phenotypes |
US9107935B2 (en) | 2009-01-06 | 2015-08-18 | Gilead Biologics, Inc. | Chemotherapeutic methods and compositions |
US8768629B2 (en) | 2009-02-11 | 2014-07-01 | Caris Mpi, Inc. | Molecular profiling of tumors |
US8927700B2 (en) | 2009-08-21 | 2015-01-06 | Gilead Biologics, Inc. | Catalytic domains from lysyl oxidase and LOXL2 |
Also Published As
Publication number | Publication date |
---|---|
WO2008138578A2 (en) | 2008-11-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2008138578A3 (en) | Methods, kits, and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy | |
WO2007072225A3 (en) | Methods and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy | |
WO2011135459A3 (en) | Methods and devices for predicting treatment efficacy | |
IL197450A0 (en) | Biomarkers of target modulation, efficacy, diagnosis and/or prognosis for raf inhibitors | |
WO2008148072A3 (en) | Disease-associated genetic variations and methods for obtaining and using same | |
TW200622950A (en) | Methods of monitoring the concentration of an analyte | |
HK1129290A1 (en) | Temperature-adjusted analyte determination for biosensor systems | |
WO2008146309A3 (en) | Genetic variants on chr 5pl2 and 10q26 as markers for use in breast cancer risk assessment, diagnosis, prognosis and treatment | |
WO2009115615A3 (en) | Detection and prognosis of cervical cancer | |
EP2170075A4 (en) | Labeled inhibitors of prostate specific membrane antigen (psma), biological evaluation, and use as imaging agents | |
WO2008091814A3 (en) | Assessment of asthma and allergen-dependent gene expression | |
BR112014031365A2 (en) | methods of detecting disease or conditions | |
WO2007047408A3 (en) | Promac signature application | |
WO2005114190A3 (en) | Methods of identifying biomarkers | |
WO2008039769A3 (en) | Methods and devices for analyzing small rna molecules | |
WO2007101190A3 (en) | Clinical applications of sto2 analysis | |
WO2010036960A3 (en) | Methods for treating, diagnosing, and monitoring lupus | |
PL1977225T3 (en) | Electrochemical biosensor analysis system | |
WO2008097908A3 (en) | Methods of diagnosing and prognosing lung cancer | |
WO2007114986A3 (en) | Cooperative probes and methods of using them | |
EP2071025A4 (en) | Primer set for amplification of ugt1a1 gene, reagent for amplification of ugt1a1 gene comprising the same, and use of the same | |
MX2013000502A (en) | Methods and kits for the diagnosis of prostate cancer. | |
WO2009055823A3 (en) | Method to predict responsiveness of breast cancer to polyaminetype chemotherapy | |
WO2009149319A3 (en) | Gene expression profiles associated with asthma exacerbation attacks | |
WO2008107114A3 (en) | Control genes for the normalization of gene expression analysis data |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08758461 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 08758461 Country of ref document: EP Kind code of ref document: A2 |